GSK plc extended its collaboration with Zhifei for the shingles vaccine Shingrix, extending exclusive rights to 2034, and anticipates up to £2.3 billion in sales from 2024 to 2029. This agreement revises and expands the partnership to also explore RSV vaccine commercialization in China.